The kit allows individuals to test for up to eight species of gastrointestinal parasites at once, with rapid and accurate results, according to a July 28 press release.
Genetic Signatures said that following the trial, it hopes to submit for FDA 510(k) clearance by late 2022.
According to the release, more than 350 million cases of gastrointestinal infections are reported in the U.S. annually, and these parasites can lead to serious infection or even death.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
